10 Best Healthcare Stocks to Buy Under $50
According to Michael Adams, the Lead Editor of Investing at Forbes, investments in healthcare stocks provide investors with consistent and steady returns because of the defensive nature of these stocks...
Cerevel Therapeutics Holdings Inc. (CERE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 10,794,876 | $441,402,480 | 10.63% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 7,539,547 | $308,292,077 | -1% | 4.1% |
| 3. | Alpine Associates Robert Emil Zoellner | 2,353,694 | $96,242,547 | +1% | 4.6% |
| 4. | Soros Fund Management George Soros | 2,151,641 | $87,980,600 | +11% | 1.58% |
| 5. | Millennium Management Israel Englander | 2,004,795 | $81,976,068 | +37% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.81 | 5,480,052 | Large Shareholder, Director | 65,679,781 | 2023-10-16 | Filing | |
| $22.81 | 5,480,052 | Large Shareholder, Director | 65,679,781 | 2023-10-16 | Filing | |
| $22.81 | 5,480,052 | Large Shareholder | 65,679,781 | 2023-10-16 | Filing | |
| $22.81 | 876,808 | Director | 10,794,876 | 2023-10-16 | Filing | |
| $23.96 | 83,857 | 83,857 | 2023-08-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $41.18 | 25,000 | 25,928 | 2024-07-01 | Filing | ||
| $40.61 | 50,000 | 15,638 | 2024-06-03 | Filing | ||
| $42.10 | 50,000 | 15,638 | 2024-05-10 | Filing | ||
| $42.33 | 50,000 | 15,638 | 2024-04-01 | Filing | ||
| $41.01 | 50,000 | 15,638 | 2024-03-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 65,679,781 | $2,784,822,714 | 60.38% | |
| 2. | 9,691,851 | $410,934,482 | 0.03% | |
| 3. | 7,374,970 | $312,698,727 | 0% | |
| 4. | 6,027,525 | $255,567,060 | 0% | |
| 5. | 2,851,819 | $120,917,126 | 0% |
News See All
9 Best Stocks to Buy in 2024 According to Billionaire George Soros
Billionaire George Soros has been one of the most active and divisive figures in the Wall Street.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Cerevel Therapeutics Third Quarter Financial Results Conference call. At this time, all participants are in listen-only mode.
5 Worst Performing Healthcare Stocks in 2023
In this article, we discuss 5 worst performing healthcare stocks in 2023.
5 Oversold Healthcare Stocks to Buy
Root, Switzerland-based NovoCure Limited (NASDAQ:NVCR) is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization...
Hedge Fund and Insider Trading News: Crispin Odey, Dan Loeb, Carl Icahn, Bridgewater Associates, Timefolio Asset Management, CVB Financial Corp (CVBF), Cerevel Therapeutics Holdings, Inc. (CERE), and More
Freddie Neave, the hedge fund manager who replaced Crispin Odey to take charge of Odey Asset Management's European Inc.
Hedge Fund and Insider Trading News: Chris Rokos, Michael Novogratz, Dan Loeb, Marshall Wace LLP, Cerevel Therapeutics Holdings Inc (CERE), Travelzoo (TZOO), and More
Billionaire Chris Rokos’s macro hedge fund posted a 3.7% gain in July, helping it to fully recover losses from earlier this year.
5 Worst Performing Biotech Stocks in 2023
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) develops treatments for neurological diseases such as schizophrenia. Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to Cerevel Therapeutics Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode.
Billionaire Hedge Funds
